Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Despite much recent progress, prostate cancer continues to represent a major cause of
cancer-related mortality and morbidity in men. Since early studies on the role of the …

Annotation of prostate cancer genomes provides a foundation for discoveries that can
impact disease understanding and treatment. Concordant assessment of DNA copy number …

Chromosomal rearrangements fusing the androgen-regulated gene TMPRSS2 to the
oncogenic ETS transcription factor ERG occur in approximately 50% of prostate cancers, but …

Findings over the past decade have identified aberrant activation of the ETS transcription
factor family throughout all stages of tumorigenesis. Specifically in solid tumours, gene …

DNA double-strand breaks (DSBs) can lead to the development of genomic rearrangements,
which are hallmarks of cancer. Fusions between TMPRSS2, encoding the transmembrane …

The discovery of recurrent gene fusions in a majority of prostate cancers has important
clinical and biological implications in the study of common epithelial tumours. Gene fusion …

All cells possess long-term, steady-state voltage gradients across the plasma membrane.
These transmembrane potentials arise from the combined activity of numerous ion channels …

Recurrent fusions of ETS genes are considered driving mutations in a diverse array of
cancers, including Ewing's sarcoma, acute myeloid leukemia, and prostate cancer. We …

The TMPRSS2-ERG fusion, present in approximately 50% of prostate cancers, is less
common in prostatic intraepithelial neoplasia (PIN), raising questions about whether …